Charles Schwab’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-137,921
| Closed | -$314K | – | 3624 |
|
|
2024
Q2 | $314K | Buy |
137,921
+116,405
| +541% | +$445K | ﹤0.01% | 3358 |
|
|
2024
Q1 | $92.9K | Hold |
21,516
| – | – | ﹤0.01% | 3310 |
|
|
2023
Q4 | $65.6K | Hold |
21,516
| – | – | ﹤0.01% | 3381 |
|
|
2023
Q3 | $31K | Sell |
21,516
-218,093
| -91% | -$422K | ﹤0.01% | 3464 |
|
|
2023
Q2 | $597K | Buy |
239,609
+35,245
| +17% | +$96.3K | ﹤0.01% | 2968 |
|
|
2023
Q1 | $548K | Buy |
204,364
+21,246
| +12% | +$102K | ﹤0.01% | 2924 |
|
|
2022
Q4 | $994K | Buy |
183,118
+2,227
| +1% | +$18.7K | ﹤0.01% | 2771 |
|
|
2022
Q3 | $2.26M | Buy |
180,891
+25,576
| +16% | +$292K | ﹤0.01% | 2551 |
|
|
2022
Q2 | $768K | Sell |
155,315
-111,030
| -42% | -$615K | ﹤0.01% | 2896 |
|
|
2022
Q1 | $2.02M | Buy |
266,345
+5,644
| +2% | +$53.5K | ﹤0.01% | 2644 |
|
|
2021
Q4 | $2.66M | Buy |
260,701
+20,568
| +9% | +$262K | ﹤0.01% | 2610 |
|
|
2021
Q3 | $3.22M | Buy |
240,133
+329
| +0.1% | +$5.36K | ﹤0.01% | 2579 |
|
|
2021
Q2 | $5.26M | Buy |
239,804
+13,054
| +6% | +$290K | ﹤0.01% | 2325 |
|
|
2021
Q1 | $5.46M | Buy |
226,750
+25,232
| +13% | +$586K | ﹤0.01% | 2257 |
|
|
2020
Q4 | $3.63M | Buy |
201,518
+519
| +0.3% | +$7.75K | ﹤0.01% | 2373 |
|
|
2020
Q3 | $2.32M | Buy |
200,999
+1,460
| +0.7% | +$24.1K | ﹤0.01% | 2445 |
|
|
2020
Q2 | $4.84M | Buy |
199,539
+13,081
| +7% | +$216K | ﹤0.01% | 2048 |
|
|
2020
Q1 | $2.06M | Buy |
186,458
+3,578
| +2% | +$66.8K | ﹤0.01% | 2268 |
|
|
2019
Q4 | $4.83M | Buy |
182,880
+3,141
| +2% | +$73.5K | ﹤0.01% | 2032 |
|
|
2019
Q3 | $4.09M | Buy |
179,739
+13,309
| +8% | +$420K | ﹤0.01% | 2075 |
|
|
2019
Q2 | $5.1M | Buy |
166,430
+26,079
| +19% | +$549K | ﹤0.01% | 1962 |
|
|
2019
Q1 | $2.33M | Buy |
140,351
+5,391
| +4% | +$102K | ﹤0.01% | 2312 |
|
|
2018
Q4 | $2.58M | Buy |
134,960
+12,042
| +10% | +$451K | ﹤0.01% | 2231 |
|
|
2018
Q3 | $6.43M | Buy |
122,918
+79,918
| +186% | +$4.36M | ﹤0.01% | 1908 |
|
|
2018
Q2 | $1.87M | Buy |
43,000
+14,100
| +49% | +$604K | ﹤0.01% | 2402 |
|
|
2018
Q1 | $1.07M | Buy |
28,900
+14,300
| +98% | +$382K | ﹤0.01% | 2494 |
|
|
2017
Q4 | $290K | Hold |
14,600
| – | – | ﹤0.01% | 2885 |
|
|
2017
Q3 | $364K | Buy |
+14,600
| New | +$270K | ﹤0.01% | 2807 |
|
Charles Schwab's GTHX Position: Q3 2024 in Review
Charles Schwab sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 137,921 shares — an estimated $314K sold.
Charles Schwab first reported a position in GTHX in Q3 2017 and held it in 28 quarters. The position peaked at $6.43M in Q3 2018. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Charles Schwab reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Charles Schwab sold 137,921 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $314K.
- Charles Schwab first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2017 and held it in 28 quarters.
- Charles Schwab's G1 Therapeutics, Inc. Common Stock position peaked at $6.43M in Q3 2018.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.